Quality of life analysis of a radiation dose-escalation study of PATIENTS with non-small-cell lung cancer a secondary analysis of the radiation Therapy Oncology Group 0617 randomized clinical trial

JAMA Oncology

Volumn 2, Issue 3, 2016, Pages 359-367

  Movsas, Benjamin ^a   Hu, Chen ^b,c   Sloan, Jeffrey ^d   Bradley, Jeffrey ^e   Komaki, Ritsuko ^f   Masters, Gregory ^g   Kavadi, Vivek ^h   Narayan, Samir ⁱ   Michalski, Jeff ^e   Johnson, Douglas W ^j   Koprowski, Christopher ^g   Curran, Walter J ^k   Garces, Yolanda I ^d   Gaur, Rakesh ^l   Wynn, Raymond B ^m   Schallenkamp, John ⁿ   Gelblum, Daphna Y ^o   MacRae, Robert M ^p   Paulus, Rebecca ^b   Choy, Hak ^q  

^a HENRY FORD HOSPITAL   (United States)

^b NRG ONCOLOGY STATISTICS AND DATA MANAGEMENT CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d MAYO CLINIC   (United States)

^e WASHINGTON UNIVERSITY   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g HELEN F GRAHAM CANCER CENTER   (United States)

^h TEXAS ONCOLOGY   (United States)

ⁱ Michigan Cancer Research Consortium   (United States)

^j Baptist Regional Cancer Institute   (United States)

^k EMORY UNIVERSITY   (United States)

^l Kansas City CCOP   (United States)

^m UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

ⁿ Montana Cancer Consortium   (United States)

^o MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^p OTTAWA REGIONAL CANCER CENTRE   (Canada)

^q UNIVERSITY OF TEXAS AT DALLAS   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; PACLITAXEL;

ADULT; AGED; CANADA; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; CONFORMAL RADIOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PROCEDURES; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION RESPONSE; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANADA; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; QUALITY OF LIFE; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME; UNITED STATES;

EID: 84987818360     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.3969     Document Type: Article

References (27)

1. Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187-199.
2. Bradley JD, Bae K, Graham MV, et al. Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117. J Clin Oncol. 2010;28(14):2475-2480.
3. Socinski MA, Blackstock AW, Bogart JA, et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol. 2008;26(15):2457-2463.
4. Schild SE, Bonner JA, Hillman S, et al. Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53). J Clin Oncol. 2007;25(21):3124-3129.
5. Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer. 1995;12(3):199-220.
6. Butt Z, Webster K, Eisenstein AR, et al. Quality of life in lung cancer: the validity and cross-cultural applicability of the Functional Assessment Of Cancer Therapy-Lung scale. Hematol Oncol Clin North Am. 2005;19(2):389-420, viii.
7. Cella D, Eton DT, Fairclough DL, et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol. 2002;55(3):285-295.
8. Agresti A. Categorical Data Analysis. 2nd ed. Hoboken, NJ: John Wiley & Sons Inc; 2002.
9. Fletcher A, Gore S, Jones D, Fitzpatrick R, Spiegelhalter D, Cox D. Quality of life measures in health care. II: Design, analysis, and interpretation. BMJ. 1992;305(6862):1145-1148.
10. Fleiss JL, Levin B, Paik MC. Statistical Methods for Rates and Proportions. Hoboken, NJ: John Wiley & Sons Inc; 2003.
11. Giobbie-Hurder A, Gelber RD, Regan MM. Challenges of guarantee-time bias. J Clin Oncol. 2013;31(23):2963-2969.
12. Dafni U. Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes. 2011;4(3):363-371.
13. Little RJ, Rubin DB. Statistical Analysis With Missing Data. 2nd ed. New York, NY: Wiley-Interscience; 2002.
14. Sarna L, Swann S, Langer C, et al. Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. Int J Radiat Oncol Biol Phys. 2008;72(5):1378-1384.
15. Basch E, Iasonos A, McDonough T, et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006;7(11):903-909.
16. Movsas B, Moughan J, Sarna L, et al. Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. J Clin Oncol. 2009;27(34):5816-5822.
17. Coates A, Porzsolt F, Osoba D. Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer. 1997;33(7):1025-1030.
18. Cella D, Herbst RS, Lynch TJ, et al. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol. 2005;23(13):2946-2954.
19. Werner-Wasik M, Swann RS, Bradley J, et al. Increasing tumor volume is predictive of poor overall and progression-free survival: secondary analysis of the Radiation Therapy Oncology Group 93-11 phase I-II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;70(2):385-390.
20. Siddiqui F, Liu AK, Watkins-Bruner D, Movsas B. Patient-reported outcomes and survivorship in radiation oncology: overcoming the cons. J Clin Oncol. 2014;32(26):2920-2927.
21. Fayers PM, Curran D, Machin D. Incomplete quality of life data in randomized trials: missing items. Stat Med. 1998;17(5-7):679-696.
22. Hallqvist A, Bergman B, Nyman J. Health related quality of life in locally advanced NSCLC treated with high dose radiotherapy and concurrent chemotherapy or cetuximab: pooled results from two prospective clinical trials. Radiother Oncol. 2012;104(1):39-44.
23. Sun A, Bae K, Gore EM, et al. Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol. 2011;29(3):279-286.
24. Movsas B, Hunt D, Watkins-Bruner D, et al. Can electronic web-based technology improve quality of life data collection? analysis of Radiation Therapy Oncology Group 0828. Pract Radiat Oncol. 2014;4(3):187-191.
25. Yom SS, Liao Z, Liu HH, et al. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2007;68(1):94-102.
26. Grills IS, Yan D, Martinez AA, Vicini FA, Wong JW, Kestin LL. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys. 2003;57(3):875-890.
27. Jiang ZQ, Yang K, Komaki R, et al. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience. Int J Radiat Oncol Biol Phys. 2012;83(1):332-339.